10-Q: BeOne Medicines Soars on BRUKINSA Sales, Narrows Losses

BeOne Medicines reported a significant increase in total revenues and product sales for Q3 and the first nine months of 2025, driven by strong global demand for BRUKINSA, leading to a substantial reduction in net losses.

Summary

• Total revenues increased 41% to $1.41 billion in Q3 2025, compared to $1.00 billion in Q3 2024, and 43.3% to $3.84 billion for the nine months ended September 30, 2025, compared to $2.68 billion in 2024.
• The company achieved a net income of $124.8 million in Q3 2025, a significant improvement from a net loss of $121.4 million in Q3 2024.
• For the nine months ended September 30, 2025, net income was $220.4 million, compared to a net loss of $492.9 million in the prior-year period.
• Global BRUKINSA (zanubrutinib) revenues increased 50.8% to $1.04 billion in Q3 2025 and 53.2% to $2.78 billion for the nine months ended September 30, 2025.
• TEVIMBRA (tislelizumab) revenues increased 16.7% to $190.6 million in Q3 2025 and 18.9% to $555.3 million for the nine months ended September 30, 2025.
• The company received an $885 million non-refundable upfront payment from Royalty Pharma for the sale of royalty rights on IMDELLTRA (tarlatamab-dlle) sales outside China.
• The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for sonrotoclax, an investigational BCL2 inhibitor, for relapsed or refractory mantle cell lymphoma (MCL).
• The European Commission (EC) approved TEVIMBRA in combination with platinum-containing chemotherapy as neoadjuvant treatment followed by monotherapy as adjuvant treatment for adult patients with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence.
• The EC also approved a new film-coated tablet formulation of BRUKINSA for all approved indications.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial performance with significant revenue growth and a return to profitability, driven by key product sales and strategic financing. Positive regulatory advancements for its pipeline further enhance its outlook, despite some minor revenue declines in other products and increased interest expenses.

Positives

• Significant revenue growth: Q3 2025 total revenue increased 41% to $1.41 billion; YTD total revenue increased 43.3% to $3.84 billion.
• Return to profitability: Q3 2025 net income of $124.8 million compared to a $121.4 million loss in Q3 2024; YTD net income of $220.4 million compared to a $492.9 million loss in YTD 2024.
• Strong BRUKINSA performance: Global revenues increased 50.8% in Q3 to $1.04 billion, maintaining a leading new patient share across the BTKi class due to its differentiated clinical profile.
• TEVIMBRA growth: Revenues increased 16.7% in Q3 to $190.6 million.
• Strategic royalty sale: Received an $885 million upfront payment from Royalty Pharma for IMDELLTRA royalties, significantly strengthening liquidity.
• Pipeline advancement: Sonrotoclax received FDA Breakthrough Therapy Designation and positive Phase 1/2 results in relapsed/refractory mantle cell lymphoma.
• Regulatory approvals: EC approval for TEVIMBRA in resectable NSCLC and a new BRUKINSA tablet formulation expand market access and product utility.
• Improved operating leverage: Gross margin percentage increased to 85.9% in Q3 2025 from 82.8% in Q3 2024, driven by a proportionally higher sales mix of global BRUKINSA and production productivity improvements.
• Strong cash position: Cash and cash equivalents increased to $4.04 billion as of September 30, 2025, from $2.63 billion at December 31, 2024.
• Positive operating cash flow: $710.2 million provided by operating activities for the nine months ended September 30, 2025, a substantial improvement from $215.8 million used in the prior-year period.

Negatives

• Interest income, net decreased by 71.5% in Q3 2025 to $3.0 million and 69.1% YTD to $12.4 million, primarily due to increased interest expense from the sale of future royalty liability and higher interest rates on debt balances, partially offset by an increase in cash and cash equivalents.
• Other (expense) income, net was a $19.0 million expense in Q3 2025 and a $6.9 million expense YTD, primarily due to impairment losses recognized on equity investments and foreign exchange losses.
• POBEVCY revenue decreased by 13.9% in Q3 2025 to $10.5 million and 12.2% YTD to $35.5 million.
• Other product revenue decreased by 22.6% in Q3 2025 to $20.1 million and 20.3% YTD to $59.2 million.
• Incurred period costs of $33.9 million related to the re-positioning of manufacturing capacity.
• Recognized an impairment loss of $15.552 million on equity investments in Q3 2025 and $12.376 million on equity-method investments in Q1 2025.

Risks

• Medicines may fail to achieve and maintain the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community necessary for commercial success.
• Limited experience in launching and marketing internally developed and in-licensed medicines, potentially hindering the generation of substantial product sales revenue.
• Substantial competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide, which may result in others commercializing competing medicines more successfully.
• Market opportunities for future medicines may be limited to specific patient populations (e.g., those ineligible for or who have failed prior treatments) and may be small.
• Inability to achieve and maintain coverage and adequate levels of reimbursement or being subject to unfavorable pricing regulations could adversely affect commercial success and business operations.
• Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
• Difficulties enrolling patients in clinical trials could delay or otherwise adversely affect clinical development activities.
• All material aspects of the research, development, manufacturing, and commercialization of pharmaceutical products are heavily regulated, and the company may face difficulties in complying with or be unable to comply with such regulations.
• The approval processes of regulatory authorities in the U.S., China, Europe, and other comparable regulatory authorities are lengthy, time-consuming, costly, and inherently unpredictable, potentially leading to delays or inability to obtain regulatory approval.
• Approved medicines and any future approved drug candidates will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and penalties for non-compliance.
• The company may be subject to anti-kickback, false claims laws, physician payment transparency laws, fraud and abuse laws, or similar healthcare and security laws and regulations, which could expose it to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished sales.
• Failure to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs could lead to additional reimbursement requirements, penalties, sanctions, and fines.
• Undesirable adverse events caused by medicines and drug candidates could interrupt, delay, or halt clinical trials, delay or prevent regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval.
• Safety, efficacy, or other issues arising with any medical product used in combination with the company's medicines could prevent marketing or cause significant regulatory delays or supply shortages.
• Recently enacted and future legislation and regulations (e.g., Inflation Reduction Act of 2022, One Big Beautiful Bill Act) may increase the difficulty and cost for obtaining regulatory approval and commercializing medicines and drug candidates, and affect prices.
• The company has historically incurred significant net losses and may incur net losses in the future, requiring additional financing.
• Inability to obtain and maintain patent protection for medicines and drug candidates may lead to loss of market exclusivities.
• Involvement in lawsuits to protect or enforce intellectual property, which could be expensive, time-consuming, and unsuccessful.
• Inability to protect the confidentiality of trade secrets could harm business and competitive position, and potential claims of wrongful use or disclosure of others' trade secrets.
• Reliance on third parties to manufacture some commercial and clinical drug supplies, with risks of non-compliance with regulations, insufficient quantities, or unacceptable quality levels or prices.
• Licensing and collaboration arrangements may not realize expected benefits.
• Failure to maintain an effective distribution channel for medicines could adversely affect business and sales.
• Inability to successfully develop and/or commercialize Amgen's oncology products could prevent expected benefits of the collaboration from materializing.
• Difficulties in managing growth due to significant increases in research, development, manufacturing, and commercial capabilities.
• Future success depends on the ability to retain key executives and to attract, retain, and motivate qualified personnel.
• Business is subject to complex and evolving industry-specific laws and regulations regarding the collection and transfer of personal data, potentially resulting in significant penalties and increased cost of operations.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties or incur costs.
• Information technology systems, or those used by contractors or collaborators, may fail or suffer security breaches, resulting in material disruption of product development and commercialization efforts.
• The increasing use of artificial intelligence-based software and social media platforms may result in reputation harm or liability.
• Failure to comply with privacy and data protection laws and regulations (e.g., China's Data Security Law, Cybersecurity Review Measures, Personal Information Protection Law) could lead to government enforcement actions and significant penalties.
• Inability to meet requirements for drug candidates and medicines if manufacturing facilities are damaged, destroyed, or production is interrupted.
• Significant costs incurred as a result of operating as a public company, with management required to devote substantial time to compliance requirements, including internal controls over financial reporting.
• Acquisitions or strategic collaborations may increase capital requirements, dilute shareholders, cause debt, or assume contingent liabilities.
• Failure to comply with the U.S. Foreign Corrupt Practices Act or other anti-bribery and corruption laws could harm reputation and lead to penalties and significant expenses.
• Financial and operating performance may be adversely affected by government shutdowns, public health crises, natural catastrophes, or other business interruptions outside of control.
• Product liability claims or lawsuits could cause substantial liabilities.
• Risks and challenges of doing business globally, including changes in political and economic policies, trade policy, currency fluctuations, and regulatory differences.
• Future operating results could be negatively affected by changes in tax rates, the adoption of new tax legislation, or exposure to additional tax liabilities.
• Changes in the political and economic policies of the PRC government or in relations between China and the U.S. or other governments, and significant oversight by the PRC government, may materially and adversely affect business.
• The PRC government may intervene or influence operations at any time, potentially limiting the ability to offer securities or causing their value to decline.
• Uncertainties regarding the interpretation and enforcement of Chinese laws, rules, and regulations, which can change quickly with little advance notice.
• Difficulties for overseas regulators to conduct investigations or collect evidence within China.
• PRC regulations establish complex procedures for some acquisitions conducted by foreign investors, making it more difficult to pursue growth through acquisitions in China.
• Reliance on dividends and other distributions on equity paid by PRC subsidiaries to fund cash and financing requirements, with potential limitations on their ability to make payments.
• Potential treatment as a resident enterprise for PRC tax purposes under the EIT Law, leading to PRC income tax on worldwide taxable income and dividends/gains on share sales.
• Uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises or other assets attributed to a PRC establishment of a non-PRC company.
• Regulations on currency exchange may limit the ability to utilize revenue effectively.
• Business benefits from certain financial incentives and discretionary policies granted by local governments; expiration of, or changes to, these incentives or policies would have an adverse effect on results of operations.
• Failure to comply with PRC regulations regarding employee equity plans and investments in offshore companies by PRC residents may subject participants or the company to fines and other sanctions.
• The pharmaceutical industry in China is highly regulated, and such regulations are subject to change, which may affect approval and commercialization of medicines and drug candidates.
• The trading prices of ordinary shares, ADSs, and/or RMB Shares can be volatile, which could result in substantial losses.
• Potential for securities litigation.
• Future sales of ordinary shares, ADSs, and/or RMB Shares in the public market could cause the share price to fall.
• The triple listing of ADSs, ordinary shares, and RMB Shares may adversely affect liquidity and value and lead to increased compliance obligations and costs.
• Reliance on price appreciation of shares for return on investment due to no expected dividends in the foreseeable future.
• Market price and trading volume could decline if securities or industry analysts do not continue to publish research, or publish inaccurate or unfavorable research.
• Shareholder rights changed as a result of the Continuation to Switzerland, potentially limiting flexibility to swiftly implement certain initiatives or strategies.
• Shareholders may face difficulties in enforcing their interests as a Swiss company.
• Voting rights of ADS holders are limited by the terms of the deposit agreement.
• Anti-takeover provisions in Swiss constitutional documents may discourage acquisition by a third party.
• Swiss Articles designate specific courts as the exclusive forum for certain shareholder disputes, potentially limiting shareholders' ability to obtain a favorable judicial forum.
• Holders of ADSs may be subject to limitations on transfer of their ADSs.
• The depositary for the ADSs is entitled to charge holders fees for various services.
• Uncertainty as to whether Hong Kong stamp duty will apply to the trading or conversion of ADSs.
• Holders of ADSs may not receive distributions on ordinary shares or any value for them if it is illegal or impractical to make them available.
• Holders of ADSs may not be able to participate in rights offerings and may experience dilution of their holdings.
• Corporate actions are substantially controlled by directors, executive officers, and other principal shareholders, who can exert significant influence over important corporate matters.
• The company may be a passive foreign investment company (PFIC) in future taxable years, which may have adverse U.S. federal income tax consequences for U.S. shareholders.
• If classified as a Controlled Foreign Corporation (CFC), Ten Percent Shareholders may be subject to adverse U.S. federal income tax consequences.
• The Continuation to Switzerland has resulted in and may continue to result in additional direct and indirect costs.
• Failure to make a required tax filing related to the Continuation could result in adverse tax consequences.
• Shareholders may be subject to Swiss withholding taxes on the payment of dividends.

Future Outlook

The company expects to achieve positive GAAP operating income for the full year 2025 as product sales growth is projected to exceed expense growth. It anticipates continued investment in selling and marketing activities as product sales increase. Management believes that current operating cash flows and existing cash and cash equivalents will be sufficient to fund operating expenses and planned long-term investments for at least the next 12 months. The company expects to repay approximately $813.3 million of loans in the next 12 months and anticipates refinancing them consistently with historical experience. The royalty period for IMDELLTRA is expected to extend at least through 2041, and the majority of the $92.89 million construction in progress for the Hopewell facility is slated to be put into service in 2026. The company does not expect the One Big Beautiful Bill Act (OBBBA) or the adoption of ASU 2023-09 (Income Tax Disclosures) to have a material impact on its consolidated financial statements, and it does not anticipate significant changes to existing unrecognized tax benefits within the next 12 months.

Management Comments

• "Our third quarter financial results show topline growth and a strong liquidity position to support ongoing operations and strategic priorities."
• "BRUKINSA is now the global revenue leader in the BTK inhibitor class."
• "Our late-stage hematology portfolio continues to advance with sonrotoclax and the BTK CDAC BGB-16673."
• "With a promising oncology pipeline, we are positioned to deliver multiple data and regulatory milestones."

Industry Context

BeOne Medicines' strong performance, particularly with BRUKINSA becoming a global revenue leader in the BTK inhibitor class, highlights its robust competitive positioning within the high-value oncology segment of the pharmaceutical industry. The company's successful navigation of global regulatory environments, evidenced by recent FDA and EC approvals for new indications and formulations, demonstrates effective R&D and market access strategies. The strategic sale of future IMDELLTRA royalties to Royalty Pharma is a common industry practice for biotech firms to secure non-dilutive financing, bolstering liquidity for further pipeline development and commercial expansion. The filing also acknowledges broader industry pressures, such as new tax legislation (OBBBA) and ongoing government scrutiny of drug pricing (Executive Orders), which are significant trends impacting pharmaceutical companies, especially in the U.S. The company's global expansion and investments in manufacturing facilities reflect a strategic move towards scaling operations and potentially reducing reliance on third-party manufacturers, a trend observed among maturing biotech companies aiming for greater control over their supply chain and cost efficiencies.

Comparison to Industry Standards

• BRUKINSA's achievement as the global revenue leader in the BTK inhibitor class indicates superior performance compared to direct competitors within this specific therapeutic area.
• The company's 41% Q3 revenue growth and 43.3% YTD revenue growth are robust indicators of market penetration and demand, likely surpassing average industry growth rates for established oncology companies.
• The significant shift from net losses to profitability (Q3 2025 net income of $124.8 million vs. Q3 2024 loss of $121.4 million) demonstrates a strong positive trajectory, potentially outperforming peers still in heavy R&D phases or facing commercialization challenges.
• The FDA Breakthrough Therapy Designation for sonrotoclax in relapsed or refractory MCL suggests a potentially best-in-class profile, positioning it favorably against existing or developing BCL2 inhibitors in the hematology space.
• The EC approval for TEVIMBRA in resectable NSCLC expands its market reach, aligning with industry efforts to broaden indications for approved therapies and maximize product lifecycle value.
• The $885 million royalty sale to Royalty Pharma is a substantial transaction, comparable to similar non-dilutive financing deals executed by other biotech companies to fund pipeline development or commercial expansion.

Corporate Governance

Legal Proceedings

• **Pharmacyclics Litigation**: Pharmacyclics LLC filed a patent infringement complaint against the company regarding BRUKINSA on June 13, 2023. The U.S. Patent and Trademark Office (USPTO) issued a Final Written Decision on April 29, 2025, invalidating all challenged claims of the patent. Pharmacyclics' request for Director Review was denied on July 17, 2025. The parties filed a joint stipulation to dismiss the infringement suit on September 30, 2025.
• **AbbVie Litigation**: AbbVie Inc. filed a complaint on September 6, 2024, alleging misappropriation of trade secrets concerning the company's Brutons tyrosine kinase (BTK) degrader program, including the lead compound BGB-16673. The company is vigorously defending against the claims and filed a motion to dismiss the complaint in its entirety on December 19, 2024.

Stakeholder Impact

• **Shareholders**: Positive impact from the return to profitability, strong revenue growth, and pipeline advancements. Potential for dilution from future equity offerings. Changes in shareholder rights and corporate governance due to the Swiss redomiciliation. Volatility in share price due to market factors and the triple listing on Nasdaq, HKEx, and STAR Market.
• **Employees**: Continued expansion of global development organization and manufacturing facilities indicates potential job growth. Share-based compensation plans are in place to incentivize employees.
• **Customers/Patients**: New regulatory approvals for TEVIMBRA in NSCLC and a new BRUKINSA formulation expand treatment options. Ongoing development of the oncology pipeline aims to provide innovative and accessible treatments.
• **Creditors**: A strong liquidity position and positive operating cash flow enhance the company's ability to meet its debt obligations. Short-term debt maturities require ongoing refinancing efforts.
• **Suppliers**: Purchase commitments for raw materials and inventory from Amgen indicate continued business relationships and demand for supplies.

Next Steps

• Continue advancing the late-stage hematology portfolio, including sonrotoclax and the BTK CDAC BGB-16673.
• Deliver multiple data and regulatory milestones from the oncology pipeline.
• Evaluate the impact of new accounting standards (ASU 2025-06, ASU 2024-03, ASU 2023-09) on financial statements.
• Repay approximately $813.3 million of short-term loans in the next 12 months and seek refinancing.
• Put the majority of the $92.89 million construction in progress for the Hopewell facility into service in 2026.
• Potentially exercise the option to sell remaining IMDELLTRA royalties for up to $65 million within one year of August 25, 2025.
• Continue investment in selling and marketing activities as product sales increase.
• Monitor and comply with evolving data protection laws and regulations in China and other jurisdictions.
• Monitor the impact of U.S. government trade negotiations and tariff policies.
• Prepare for National Reimbursement Drug List (NRDL) negotiations in China for eligible medicines/indications annually.

Key Dates

Recommendation

BeOne Medicines has demonstrated a strong turnaround, moving from significant net losses to profitability driven by robust sales of its flagship product, BRUKINSA, which has become a global leader in its class. The substantial revenue growth across its portfolio, coupled with strategic financing through the IMDELLTRA royalty sale, significantly strengthens its financial position and liquidity. Positive clinical and regulatory milestones for sonrotoclax and TEVIMBRA indicate a promising pipeline and continued market expansion potential. While the company faces ongoing R&D investments and regulatory complexities, the current trajectory of increasing sales, improved operating leverage, and a solid cash balance suggests a strong growth outlook, making it an attractive investment.

Keywords

Oncology, Biotechnology, Pharmaceuticals, BRUKINSA, TEVIMBRA, SEC Filing, 10-Q, Financial Results, Revenue Growth, Net Income, Clinical Trials, Regulatory Approval, Risk Factors, Corporate Governance, Switzerland, China, Amgen, Royalty Pharma, sonrotoclax, BCL2 inhibitor, NSCLC, MCL